Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
Sponsor: Kartos Therapeutics, Inc.
ClinicalTrials ID:NCT05797831
This clinical trial assesses navtemadlin as maintenance therapy in patients with TP53WT advanced or recurrent endometrial cancer post-chemotherapy response. It includes two parts: Part 1 focuses on safety and efficacy of two navtemadlin doses, while Part 2 compares the Phase 3 dose to placebo. Eligible participants must have ECOG 0-1, confirmed diagnosis, and adequate organ function. Navtemadlin is an oral MDM2 inhibitor.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who have achieved complete response or partial response on chemotherapy.
The study will be conducted in 2 parts. Part 1 will evaluate safety and efficacy of two different doses of navtemadlin alongside an observational control arm to determine the Phase 3 navtemadlin dose. Part 2 will evaluate the efficacy and safety of navtemadlin Phase 3 dose compared to placebo.
Eligibility Criteria
Inclusion Criteria
- ECOG 0-1
- Histologically or cytologically confirmed diagnosis of endometrial cancer documented as TP53WT
- Subjects with advanced or recurrent disease must have completed a single line of up to 6 cycles of taxane-platinum based chemo and achieved a CR or PR per RECIST V1.1
- Adequate hematologic, hepatic and renal function (within 14 days)
Exclusion Criteria
- Has any sarcomas or small-cell carcinomas with neuroendocrine differentiation
- Prior immune therapy, cytokine therapy, or any investigational therapy (within 28 days)
- Indwelling surgical drains
- Grade 2 or higher QTc prolongation
- History of major organ transplant
- History of bleeding diathesis; major hemorrhage or intracranial hemorrhage (within 24 weeks)
Get This Program In Your Inbox
You can sign up and apply your patients for this program.